Agc Biologics SpA

Agc Biologics SpA is a company in Bresso Mi, Italy that has taken part in 6 EU-funded projects since 2009, receiving €6.7M in EU funding and leading 1 as coordinator.

EU funding received€6.7M
EU projects6
As coordinator1
Running now0
First EU project2009
Latest project2017
CountryItaly
EU registration (PIC)998198968
On this page · 5 sections→

Where the EU money came from

Funding by EU programme. Amounts are Agc Biologics SpA's own share of each project, not the project's full budget.

  • FP7 (2007 to 2013)€4.4M · 5 projects
  • Horizon 2020€2.3M · 1 project

Projects

6 EU-funded projects, newest first. Agc Biologics SpA led 1 of them as coordinator. Each links to the official record.

  • EURE-CARTCoordinator

    EURopean Endeavour for Chimeric Antigen Receptor Therapies

    Horizon 2020 · 2017–2021 · Project on CORDIS ↗

    €2.3Mtheir share
  • SUPERSISTPartner

    Towards clinical translation of new gene targeting technologies for correcting inherited mutations and empowering adoptive immunotherapy of cancer

    FP7 (2007 to 2013) · 2013–2016 · Project on CORDIS ↗

    €2.4Mtheir share
  • CELL-PIDPartner

    Advanced Cell-based Therapies for the treatment of Primary ImmunoDeficiency

    FP7 (2007 to 2013) · 2010–2016 · Project on CORDIS ↗

    €678ktheir share
  • ATTRACTPartner

    Advanced Teaching and TRaining for Adoptive Cell Therapy

    FP7 (2007 to 2013) · 2009–2013 · Project on CORDIS ↗

    €202ktheir share
  • PERSISTPartner

    Persisting Transgenesis

    FP7 (2007 to 2013) · 2009–2013 · Project on CORDIS ↗

    €312ktheir share
  • OPTISTEMPartner

    Optimization of stem cell therapy for clinical trials of degenerative skin and muscle diseases

    FP7 (2007 to 2013) · 2009–2013 · Project on CORDIS ↗

    €759ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

Fields it works in

Research fields recorded on its Horizon projects.

  • cells technologies
  • employment
  • gene therapy
  • immunology
  • immunotherapy
  • leukemia
  • muscular dystrophies
  • mutation
  • oncology
  • pharmaceutical drugs
  • pharmacology and pharmacy
  • squamous cell carcinoma
  • stem cells
  • toxicology

Is this your organisation?

Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.

Claim this profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships. Official website ↗

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime